diabetestalk.net

Is Tresiba The Same As Novolog

Fiasp Insulin, Insulin Aspart, Fiasp Vs Novolog

Fiasp Insulin, Insulin Aspart, Fiasp Vs Novolog

Insulin aspart is a powerhouse in the world of diabetes . It was introduced under the brand name Novolog in June of 2000. For over 15 years, Novolog has been a staple of insulin regimens for many patients. Novolog and Humalog are the two most commonly prescribed fast-acting insulins that patients take within 15 minutes of mealtime. For this article, we will be paying closer attention to insulin aspart (more commonly called Novolog or Novorapid® in Europe and Canada). Novolog itself is an insulin analogue. This means it has been modified from regular insulin to change its structure and how quickly it is absorbed from under the skin. Novo Nordisk teamed up their workhorse Novolog insulin with a B3 vitamin (nicotinamide) to make it absorb more quickly and the amino acid arginine to stabilize it. That’s right! Fiasp insulin is simply Novolog with two small additions: Vitamin B3 and naturally occurring arginine. Researchers discovered that adding nicotinamide to the insulin aspart molecule causes its initial absorption to happen more quickly. This means it acts more like the insulin normally made by your pancreas . Fiasp insulin can even be taken up to 20 minutes AFTER starting the meal! So if Fiasp were racing Novolog, it could give Novolog a 15-minute head start and still catch up! Not only that, but twice as much insulin is available within 30 minutes of injecting Fiasp as compared to Novolog . More insulin available earlier means more insulin is in the body to handle the sugar entering your blood stream after eating. So what are the key differences between Novolog and Fiasp? Here is a quick summary: Beginning of meal, up to 20 minutes after Added nicotinamide for faster absorption and L-arginine for stability Pricing has not been finalized in the USA Fiasp is in a cl Continue reading >>

Novolog Flexpen And Tresiba Drug Interactions - Drugs.com

Novolog Flexpen And Tresiba Drug Interactions - Drugs.com

Do not stop taking any medications without consulting your healthcare provider. Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist. Some mixtures of medications can lead to serious and even fatal consequences. Continue reading >>

Tresiba Side Effects Center

Tresiba Side Effects Center

Tresiba (insulin degludec injection) is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Common side effects of Tresiba include: allergic reactions, injection site reactions, itching, rash, swelling, weight gain, upper respiratory tract infection, headache, upset stomach or stomach pain, and diarrhea. The dose of Tresiba is individualized based on type of diabetes, metabolic needs, blood glucose monitoring results, and glycemic control goal. Tresiba may interact with other insulin products, beta-blockers, clonidine, guanethidine, reserpine, other antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs, sulfonamide antibiotics, GLP-1 receptor agonists, DDP-4 inhibitors, SGLT-2 inhibitors, atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetic agents, thyroid hormones, alcohol, lithium salts, or pentamidine. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant while taking Tresiba. During pregnancy, Tresiba should only be taken if prescribed. It is unknown if Tresiba passes into breast milk. Women with diabetes who are nursing may require adjustments in insulin dose, meal plan, or both. Consult your doctor before breastfeeding. Our Tresiba (insulin degludec injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. This is not a complete list of s Continue reading >>

Fda Approves Ultra-long-acting Basal Insulin Tresiba – Take It At Any Time Of Day!

Fda Approves Ultra-long-acting Basal Insulin Tresiba – Take It At Any Time Of Day!

Twitter Summary: @US_FDA approves next-gen once-daily basal #insulin Tresiba, plus Xultophy (Victoza + Tresiba) now submitted Novo Nordisk recently announced the FDA approval of the next-generation once-daily basal insulin Tresiba (insulin degludec) and the premixed insulin Ryzodeg (70/30 mixture of insulin degludec and insulin aspart). Tresiba will be launched in early 2016 and will come in prefilled FlexTouch pens. The insulin will launch in two concentrations (U100 or U200), enabling maximum doses of 80 units or 160 units per injection. Exact pricing information is unavailable at this time and we're really hoping that it's priced similarly to Levemir. What makes Tresiba exciting? Several things: Flatter profile: Tresiba lowers blood sugar in a flatter, more predictable way than Levemir or Lantus. Less nighttime hypoglycemia: In certain trials, Tresiba seemed to cause less nighttime hypoglycemia vs. Lantus. This is not exactly “on the label,” but it seems to be true in the "real world” according to doctors with experience with Tresiba. Dosing Flexibility: Tresiba can be taken at any time throughout the day – for example, 8 am on Monday, 12 pm on Tuesday, and 7 am on Wednesday. The insulin lasts for an impressive 42 hours (at least), and doses must be taken at least eight hours apart. This flexibility is a major plus, as all other basal insulins (Levemir, Lantus, Toujeo) must be taken at the same time every day according to the label (though Toujeo gets reports in the real world of also having some further flexibility). Fewer Injections for those using high doses of insulin: Patients can take up to 160 units of Tresiba in a single injection with the U200 pen, which means most patients should be able to take a day’s worth of insulin in a single dose. Toujeo is Continue reading >>

Selected Important Safety Information

Selected Important Safety Information

Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening Tresiba® (insulin degludec injection) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. Tresiba® is not recommended for treating diabetic ketoacidosis or for pediatric patients requiring less than 5 units of Tresiba®. Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment Accidental mix-ups betwe Continue reading >>

Product Important Safety Information

Product Important Safety Information

Selected Important Safety Information WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. Victoza® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Victoza® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Victoza®. Selected Important Safety Information Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients Levemir® is contraindicated in patients with hypersensitivity to Levemir® or any of its excipients NovoLog® and NovoLog® Mix 70/30 are contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin aspart or any of the excipients Warnings and Precautions Never Share a Tresiba® FlexTouch®; Levemir® FlexTouch®, NovoLog® FlexPen, NovoLog®FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device; or NovoLog®Mix 70/30 FlexPen® Between Patients, even if the needle is changed. Patients using vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens Hypoglyc Continue reading >>

Taking Shots At The Same Time Affect Anything?

Taking Shots At The Same Time Affect Anything?

Taking shots at the same time affect anything? Taking shots at the same time affect anything? Does taking Lantus about 15 mins before novolog have any affect on how well or fast the novolog works? It seems I always needs more novolog if I take it around my lantus. Or it doesn't work as well. Is there any truth to this? Does taking Lantus about 15 mins before novolog have any affect on how well or fast the novolog works? It seems I always needs more novolog if I take it around my lantus. Or it doesn't work as well. Is there any truth to this? Don't take them in the exact same spot. Other than that, nope. When you say the same spot do you mean my entire stomach or arm as the same spot or the same injection site. Moderator Type1 - Minimed 640G - Enlite CGM Just shoot at least a few inches away from your previous shot. When you say the same spot do you mean my entire stomach or arm as the same spot or the same injection site. I forget the reason, but I think it has to do with the Ph of the Lantus and the Novolog being different. If they are mixed together, even in your body (inject the two within an inch from each other) one will weaken the other / or both. Seperate legs, arms, or sides of the stomache and you should have no issues. The timing could be more to do with the fact that your Lantus is running out when you take your new shot. You should be perfectly fine to take both at the same time, I do it all the time - but I tend to use different areas - one in the left leg and one in the right - or at least a good gap between the jabs. The cure *could* be chocolate. I'm experimenting D.D. Family type 1 LADA new pumper via MM-522 The timing could be more to do with the fact that your Lantus is running out when you take your new shot. You should be perfectly fine to take bot Continue reading >>

Novolog And Tresiba Drug Interactions - Drugs.com

Novolog And Tresiba Drug Interactions - Drugs.com

Do not stop taking any medications without consulting your healthcare provider. Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist. Some mixtures of medications can lead to serious and even fatal consequences. Continue reading >>

Novo Nordisk Patient Assistance Program

Novo Nordisk Patient Assistance Program

The Novo Nordisk Patient Assistance Program (PAP) encompasses our goal of continued commitment to people living with diabetes and the Novo Nordisk Triple Bottom Line. The Diabetes PAP provides free medicine to those who qualify. If approved, a free 120-day supply of medicine will be sent to the prescribing health care providers' office to be picked up at the patient's convenience. Novo Nordisk will automatically contact the health care provider 80 days later to approve the medication refill. If you are a patient in need of assistance or know someone in need of assistance, follow these 3 simple steps to see if you qualify for free diabetes medication from Novo Nordisk: 1) Complete the “For Patient”, “Patient Signature”, and “Date” sections on the application 2) Gather proof of income 3) Take application and proof of income to your health care provider to complete the Health Care Practitioner section of your application. Patients and care givers can also obtain more information and access to the program by calling the Novo Nordisk Patient Assistance Program toll free at 866-310-7549. Patients can also obtain information by visiting Cornerstones4Care.com. If you are a health care professional and you want additional information about the Novo Nordisk Patient Assistance Program, have eligible patients who are not yet enrolled, or have patients who are enrolled and want additional information about their eligibility, please visit NovoMedLink.com. How to Apply Please either download the application below (if available) or go to the program website for more information on how to apply. Once you fill out your application, send it to the address on the application. Remember not to send program applications to PPA. Continue reading >>

Novolog Rapid-acting Insulin | Novolog (insulin Aspart Injection) 100 U/ml

Novolog Rapid-acting Insulin | Novolog (insulin Aspart Injection) 100 U/ml

Do not share your Fiaspwith other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them. your blood sugar is too low (hypoglycemia) or you are allergic to any of its ingredients. Before taking Fiasp, tell your health care provider about all your medical conditions including, if you: are pregnant or breastfeeding or plan to become pregnant or breastfeed. It is not known if Fiasp passes into your breast milk. are taking new prescription or over-the-counter medicines, including supplements. Talk to your health care provider about low blood sugar and how to manage it. Do not share your Fiaspwith other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them. your blood sugar is too low (hypoglycemia) or you are allergic to any of its ingredients. Before taking Fiasptell your health care provider about all your medical conditions including, if you: are pregnant or breastfeeding or plan to become pregnant or breastfeed. It is not known if Fiasppasses into your breast milk. are taking new prescription or over-the-counter medicines, including supplements. Talk to your health care provider about low blood sugar and how to manage it. Read the Instructions for Useand take Fiaspexactly as your health care provider tells you to. Fiaspstarts acting fast.You should take your dose of Fiaspat the beginning of the meal or within 20 minutes after starting a meal. Know the type and strength of your insulin.Do notchange your insulin type unless your health care provider tells you to. If you miss a dose of Fiaspmonitor your blood sugar levels to decide if an insulin dose is needed. Continue with your regular dosing schedule at the next meal. Check Continue reading >>

Is Newly Approved Tresiba The Best Long-acting Insulin?

Is Newly Approved Tresiba The Best Long-acting Insulin?

Comparing long-acting insulins? Newly approved Tresiba may come out ahead. With the exception of NPH insulin (the original long-acting insulin—examples include Humulin N and Novolin N), they are all going to cost you. So, if you are already paying big bucks for your long-acting insulin, here are some things to think about: What does a long-acting or basal insulin do for me? This is your baseline insulin, the insulin that is secreted to control your sugars when you are not eating (in the fasting state). Put another way, basal Insulin is used to suppress liver glucose production and help you maintain normal sugars even when you aren’t eating. What are my options? The old-school and well respected NPH insulin has been around forever and is considered intermediate acting. Levemir and Lantus were then joined this year by Toujeo and now Tresiba as the main players. Toujeo is basically Lantus (which was losing its patent) and may not gain any traction in the market. These insulins are typically administered once daily to provide basal insulin levels. Basaglar was just approved by the FDA and think of Basaglar as the Lantus “generic” or copycat–that will be available soon and let’s hope it’s cheaper than Lantus. What is Tresiba? Tresiba (insulin degludec) is the longest acting insulin available and there don’t appear to be any coming down the pipeline that give this duration of coverage. What makes Tresiba a hero is the long duration of action (>40 hours) with less fluctuation in blood levels of the drug. It’s given once a day. Is Tresiba the best long-acting insulin? This can only be answered on an individual basis and along with your provider. Lantus, Levemir and Tresiba may have some modest advantages over NPH (less symptomatic and nighttime hypoglycemia) i Continue reading >>

Insulin Wars: New Ultra Long-lasting Basal Insulin Tresiba Okd By Fda

Insulin Wars: New Ultra Long-lasting Basal Insulin Tresiba Okd By Fda

Let's face it, we all appreciate the insulin that keeps us alive, but wish it worked more effectively and was easier to dose. Novo Nordisk's latest innovation, new ultra long-lasting Tresiba basal insulin, is potentially huge news for people with diabetes (PWDs) because it offers options on when and how we take our insulin. It actually has the potential to last for nearly two days between doses (!). On Sept. 25, the New Jersey-based Pharma giant received word from the FDA that it had the green light to begin selling Tresiba insulin in the U.S. Known in official medical lingo as "insulin degludec" but sold under brand name Tresiba (pronounced Tra-seeba), the product is already available in 30 countries around the globe, and will begin shipping here in the States in late 2015 or early 2016. On the same day, the FDA also approved Novo's secondary 70/30 insulin mix known as Ryzodeg, which is a combo of 70% Tresiba basal and 30% rapid-acting NovoLog insulin. That means you can take this insulin mix with a meal, and get both the short- and long-term effects of these Novo insulins. These approvals are a big milestone for Novo, coming two years after the FDA first shot down Tresiba approval based on concerns over cardiovascular risks; the company conducted a number of additional clinical studies since and submitted the new data earlier this year. Although it's ideal practice, most of us patients find it next to impossible to take our insulin at the exact same time every single day. So with Tresiba's long-lasting effectiveness and the combo Ryzodeg adding in a meal-time insulin, we get much more flexibility for successful dosing. What's Really Different About Tresiba? What's new about Tresiba is that it is actually a long-lasting basal insulin. It stays effective for 42 hours be Continue reading >>

Recommended Medication Request Guidelines

Recommended Medication Request Guidelines

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES INSULIN (SUBCUTANEOUS) Generic Brand HICL GCN Exception/Other INSULIN ASPART NOVOLOG, NOVOLOG FLEXPEN 20769 INSULIN ASPART PROTAMINE/ASPART NOVOLOG MIX 70/30, NOVOLOG - MIX 70-30 FLEXPEN 23400 INSULIN NPH HUMAN ISOPHANE NOVOLIN N 00780 BRAND ≠HUMULIN N, HUMULIN N KWIKPEN INSULIN NPH/REG NOVOLIN 70/30 06215 BRAND ≠HUMULIN 70- 30, HUMULIN 70/30 KWIKPEN INSULIN REGULAR HUMAN NOVOLIN R 00768 BRAND ≠AFREZZA INSULIN DEGLUDEC TRESIBA FLEXTOUCH 40844 INSULIN GLARGINE BASAGLAR 98637 BRAND ≠LANTUS SOLOSTAR GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for Novolin or a Novolog insulin product (includes Relion Novolin)? If yes, continue to #2. If no, continue to #4. 2. Has the patient tried and failed therapy with comparable formulation of Humulin or Humalog, or does the patient have a contraindication to Humulin or Humalog? If yes, continue to #7. If no, continue to #3. CONTINUED ON NEXT PAGE HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Revised: 07/14/2017 Page 2 INSULIN (SUBCUTANEOUS) INITIAL CRITERIA (CONTINUED) 3. Did the provider indicate the patient would be unable to utilize Humulin or Humalog because of visual, physical or functional impairment? If yes, continue to #7. If no, do not approve. Please use status code #238 and the denial text provided. DENIAL TEXT: Per your health plan's Insulin guideline, a trial with a similar formulation of [Humulin or Humalog] is required prior to approving coverage of the requested medication except when the preferred medication cannot be used due to significant visual, physical or functional impairment. Your physician did not indicate that you have tried [Humulin or Humalog] or y Continue reading >>

Apidra And Tresiba - Type 1 Diabetes - Diabetes Forums

Apidra And Tresiba - Type 1 Diabetes - Diabetes Forums

Registration is fast, simple and absolutely free so please,join our community todayto contribute and support the site. This topic is now archived and is closed to further replies. I am currently using Novorapid (Novolog in the US) as bolus and Basalog (A biosimilar of Insulin Glargine) as basal. I have been using these for 2 years. They are obviously much better than the human insulin I used for a few months following diagnosis, but I am thinking if there are better insulins out there. I would like to know more about Apidra (insulin glulisine) and Tresiba (insulin degludec) based on the experience of those who have used it for some time. Insulin Glargine is supposed to be peakless, but for me, there is a significant peak about 5 hours after injection. Even after splitting to 2 doses, in the morning (7 am) and in the evening (7 pm), this effect can be seen. This may be because I am very skinny. So I always have to eat some snacks between my meals at around 11 am and before bed. While this maybe desirable for some, it really kills my appetite and I would like to avoid it if possible. That's why I am considering switching to Tresiba. About apidra, I have read it has a different profile when compared to novolog and humalog. How exactly is it different? Does it have any advantage over the other two? Though I've been on MDI only two years, because of insurance coverage changes in what insulin they will cover, I've been on all three fast-acting insulins over that period, first Novolog, then Humalog and currently Apidra. I have a strong preference for Apidra. Novolog took the longest to finish the insulin action for me. Because we are "creative cooks" and it is often difficult to calculate exactly how many carbs are in the food when we don't follow the same recipe repeatedly, Continue reading >>

Novo Nordisk Savings Card

Novo Nordisk Savings Card

Eligibility and Restrictions: In order to redeem this offer patient must have a valid prescription for the brand being filled. A valid Prescriber ID# is required on the prescription. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. The brand and the prescription being filled must be covered by the patient’s commercial insurance plan. Offer excludes full cash-paying patients. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described herein and will not seek reimbursement for any benefit received through this card. Novo Nordisk’s Eligibility and Restrictions, and Offer Details may change from time to time, and for the most recent version, please visit this webpage. Re-confirmation of information may be requested periodically to ensure accuracy of data and compliance with terms. Patients with questions about the Savings Card offer may call 1-877-304-6855. This offer is valid in the United States and may be redeemed at participating retail pharmacies. Absent a change in Massachusetts law, effective July 1, 2019, the Savings Card will no longer be valid for residents of Massachusetts. Void where taxed, restricted, or prohibited by law. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. C Continue reading >>

More in diabetes